Allergan Aesthetics, an AbbVie Company, Acquires Innovative Luminera Dermal Filler Business

Rhea-AI Summary

Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced its agreement to acquire Luminera, an Israel-based aesthetics company specializing in dermal fillers. This acquisition will enhance Allergan's existing JUV DERM® filler portfolio with Luminera's innovative products, including the differentiated HArmonyCa filler. The deal aims to strengthen Allergan Aesthetics' position in the global aesthetics market, providing new offerings for healthcare professionals and patients. The full dermal filler portfolio will also support international development opportunities.

Positive

• Acquisition strengthens Allergan's JUV DERM® filler portfolio.
• Luminera's HArmonyCa filler offers differentiation in the market.
• Enhancement of product offerings for healthcare professionals and patients.

Negative

• None.

IRVINE, Calif., Oct. 7, 2020 /PRNewswire/ -- Today Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that it has entered into an agreement with Luminera, a privately held, aesthetics company based in Israel with a portfolio and pipeline of dermal filler products. 

Under the terms of the agreement, Allergan Aesthetics will acquire Luminera's full dermal filler portfolio and R&D pipeline further enhancing Allergan Aesthetics' leading dermal filler portfolio with its JUV DERM^® collection of fillers. 

"The addition of the Luminera assets adds innovative technology, complementing our leading JUV DERM^® filler franchise.  We welcome the Luminera team as we continue to build our global aesthetics company and a world-class product offering for healthcare professionals and patients around the world," said Carrie Strom, SVP, AbbVie, and President, Global Allergan Aesthetics.

Luminera Chairman Dadi Segal, PhD, added, "We believe bringing together key, innovative Luminera assets with the support of Allergan Aesthetics will provide an even brighter future for our people, products and a more expanded offering for our customers.  This is a tremendous opportunity to further build, develop and collaborate with a leading global aesthetics company."

Luminera's key value driver for the future is HArmonyCa, an innovative dermal filler intended for facial soft tissue augmentation comprised of a combination of cross-linked hyaluronic acid (HA) with embedded calcium hydroxyapatite (CaHA) microspheres.  The combination of HA and CaHA in a single product is  highly differentiated in the dermal filler category. HArmonyCa is currently commercially available in Israel and Brazil.

Allergan Aesthetics will continue to develop this product for its International and US markets.

The Luminera dermal filler portfolio also includes a line of HA dermal fillers, as well CaHA based fillers commercialised across several markets.  Brands include Crystalys, Hydryalix and Hydryal.

About Allergan Aesthetics

At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.AllerganAesthetics.com.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

View original content:http://www.prnewswire.com/news-releases/allergan-aesthetics-an-abbvie-company-acquires-innovative-luminera-dermal-filler-business-301147404.html

SOURCE AbbVie

FAQ

What is the purpose of AbbVie's acquisition of Luminera?

The acquisition aims to enhance Allergan Aesthetics' dermal filler portfolio, especially its JUV DERM® collection, by integrating Luminera's innovative products.

What are the key products included in the Luminera acquisition?

The acquisition includes Luminera's full dermal filler portfolio, notably the HArmonyCa filler, along with other HA and CaHA-based fillers.

When was the acquisition agreement announced?

The acquisition agreement was announced on October 7, 2020.

How does this acquisition impact AbbVie stock (ABBV)?

The acquisition could positively impact AbbVie stock by expanding its product offerings in the aesthetics market, potentially leading to increased revenue.

Where are Luminera's products currently available?

Luminera's products, including HArmonyCa, are currently available in Israel and Brazil.